Cancer stem cells

Zuoren Yu; Timothy G. Pestell; Michael P. Lisanti; Richard G. Pestell

doi:10.1016/j.biocel.2012.08.022

Cancer stem cells

Zuoren Yu, Timothy G. Pestell, Michael P. Lisanti, Richard G. Pestell

Research output: Contribution to journal › Article › peer-review

Abstract

Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with capabilities of self-renewal, differentiation, and tumorigenicity when transplanted into an animal host. A number of cell surface markers such as CD44, CD24, and CD133 are often used to identify and enrich CSCs. A regulatory network consisting of microRNAs and Wnt/β-catenin, Notch, and Hedgehog signaling pathways controls CSC properties. The clinical relevance of CSCs has been strengthened by emerging evidence, demonstrating that CSCs are resistant to conventional chemotherapy and radiation treatment and that CSCs are very likely to be the origin of cancer metastasis. CSCs are believed to be an important target for novel anti-cancer drug discovery. Herein we summarize the current understanding of CSCs, with a focus on the role of miRNA and epithelial-mesenchymal transition (EMT), and discuss the clinical application of targeting CSCs for cancer treatment. © 2012 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	2144-2151
Number of pages	7
Journal	International Journal of Biochemistry and Cell Biology
Volume	44
Issue number	12
DOIs	https://doi.org/10.1016/j.biocel.2012.08.022
Publication status	Published - Dec 2012

Keywords

Cancer stem cells
Metastasis
MiRNA
Relapse
Tumorigenesis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biocel.2012.08.022

Cite this

@article{5568a1f74cc8493b9dd15c1ad7f20971,

title = "Cancer stem cells",

abstract = "Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with capabilities of self-renewal, differentiation, and tumorigenicity when transplanted into an animal host. A number of cell surface markers such as CD44, CD24, and CD133 are often used to identify and enrich CSCs. A regulatory network consisting of microRNAs and Wnt/β-catenin, Notch, and Hedgehog signaling pathways controls CSC properties. The clinical relevance of CSCs has been strengthened by emerging evidence, demonstrating that CSCs are resistant to conventional chemotherapy and radiation treatment and that CSCs are very likely to be the origin of cancer metastasis. CSCs are believed to be an important target for novel anti-cancer drug discovery. Herein we summarize the current understanding of CSCs, with a focus on the role of miRNA and epithelial-mesenchymal transition (EMT), and discuss the clinical application of targeting CSCs for cancer treatment. {\textcopyright} 2012 Elsevier Ltd. All rights reserved.",

keywords = "Cancer stem cells, Metastasis, MiRNA, Relapse, Tumorigenesis",

author = "Zuoren Yu and Pestell, {Timothy G.} and Lisanti, {Michael P.} and Pestell, {Richard G.}",

note = "P30 CA056036, NCI NIH HHS, United StatesP30CA056036, NCI NIH HHS, United StatesR01 CA070896, NCI NIH HHS, United StatesR01 CA075503, NCI NIH HHS, United StatesR01 CA086072, NCI NIH HHS, United StatesR01 CA107382, NCI NIH HHS, United StatesR01 CA132115, NCI NIH HHS, United StatesR01CA070896, NCI NIH HHS, United StatesR01CA075503, NCI NIH HHS, United StatesR01CA086072, NCI NIH HHS, United StatesR01CA107382, NCI NIH HHS, United StatesR01CA132115, NCI NIH HHS, United States",

year = "2012",

month = dec,

doi = "10.1016/j.biocel.2012.08.022",

language = "English",

volume = "44",

pages = "2144--2151",

journal = "International Journal of Biochemistry and Cell Biology",

issn = "1357-2725",

publisher = "Elsevier BV",

number = "12",

}

TY - JOUR

T1 - Cancer stem cells

AU - Yu, Zuoren

AU - Pestell, Timothy G.

AU - Lisanti, Michael P.

AU - Pestell, Richard G.

N1 - P30 CA056036, NCI NIH HHS, United StatesP30CA056036, NCI NIH HHS, United StatesR01 CA070896, NCI NIH HHS, United StatesR01 CA075503, NCI NIH HHS, United StatesR01 CA086072, NCI NIH HHS, United StatesR01 CA107382, NCI NIH HHS, United StatesR01 CA132115, NCI NIH HHS, United StatesR01CA070896, NCI NIH HHS, United StatesR01CA075503, NCI NIH HHS, United StatesR01CA086072, NCI NIH HHS, United StatesR01CA107382, NCI NIH HHS, United StatesR01CA132115, NCI NIH HHS, United States

PY - 2012/12

Y1 - 2012/12

N2 - Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with capabilities of self-renewal, differentiation, and tumorigenicity when transplanted into an animal host. A number of cell surface markers such as CD44, CD24, and CD133 are often used to identify and enrich CSCs. A regulatory network consisting of microRNAs and Wnt/β-catenin, Notch, and Hedgehog signaling pathways controls CSC properties. The clinical relevance of CSCs has been strengthened by emerging evidence, demonstrating that CSCs are resistant to conventional chemotherapy and radiation treatment and that CSCs are very likely to be the origin of cancer metastasis. CSCs are believed to be an important target for novel anti-cancer drug discovery. Herein we summarize the current understanding of CSCs, with a focus on the role of miRNA and epithelial-mesenchymal transition (EMT), and discuss the clinical application of targeting CSCs for cancer treatment. © 2012 Elsevier Ltd. All rights reserved.

AB - Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with capabilities of self-renewal, differentiation, and tumorigenicity when transplanted into an animal host. A number of cell surface markers such as CD44, CD24, and CD133 are often used to identify and enrich CSCs. A regulatory network consisting of microRNAs and Wnt/β-catenin, Notch, and Hedgehog signaling pathways controls CSC properties. The clinical relevance of CSCs has been strengthened by emerging evidence, demonstrating that CSCs are resistant to conventional chemotherapy and radiation treatment and that CSCs are very likely to be the origin of cancer metastasis. CSCs are believed to be an important target for novel anti-cancer drug discovery. Herein we summarize the current understanding of CSCs, with a focus on the role of miRNA and epithelial-mesenchymal transition (EMT), and discuss the clinical application of targeting CSCs for cancer treatment. © 2012 Elsevier Ltd. All rights reserved.

KW - Cancer stem cells

KW - Metastasis

KW - MiRNA

KW - Relapse

KW - Tumorigenesis

U2 - 10.1016/j.biocel.2012.08.022

DO - 10.1016/j.biocel.2012.08.022

M3 - Article

C2 - 22981632

SN - 1357-2725

VL - 44

SP - 2144

EP - 2151

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

IS - 12

ER -

Cancer stem cells

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this